Abstract 4529
Background
First line therapies usually induce the longest progression free survival (PFS) in advanced/metastatic cancer as compared to subsequent lines of treatment. However, immunotherapy (IT) due to its mechanisms of action could influence sensitivity to conventional cancer therapy (CCT) after progression to IT and thereby, influence both tumor growth rate (TGR) and progression free survival (PFS). We have studied TGR and PFS before and after participation in phase I IT trials.
Methods
We retrospectively studied 173 patients who were enrolled in Phase I IT trials at our institution between January 2012 and September 2017. Patients should have received at least one line of CCT before and after IT. Baseline characteristics (sex, age, tumor type, presence of liver disease, number of CCT lines prior to IT, type of CCT and IT) were recorded. PFS before and after IT was calculated. A ratio of PFS after/before IT (PFSaftIT /PFSbefIT) over 1.2 was considered clinically significant. TGR was calculated based on the formulas: TGR = 100 (exp(TG)−1), TG = 3 Log(Dt/D0)/t.
Results
37 patients met inclusion criteria. Baseline characteristics are shown in the table. Nine of 37 patients (6 CRC, 3 renal cancer) presented a PFSaftIT/PFSbefIT rate over 1.2. Regarding TGR, of 16 patients in whom TGRpre and TGRpost were available, 3 patients (2 CRC, 1 NSCLC) presented a decrease in TGR greater than 15% when given treatment after IT therapy.Table: 1228P
| Characteristics | N = 37 |
| Female | 17 |
| Median (M) age at diagnosis (range) | 55 (31-79) |
| M lines prior to IT (range) | 2 (1-5) |
| Primary tumor Gastrointestinal Genitourinary Gynecological NSCLC Head and neck Breast cancer | 19 7 5 4 1 1 |
| Presence of liver disease (pre/IT/pro) | 15/18/31 |
| CCT class (pre/post IT) Platinum derivatives Other alkylating agents (a) Antimetabolites a Anthracyclines Topoisomerase inhibitors (i) Antimicrotubules a Antiangiogenic a Signal transduction i Immunotherapy Others | 14/18 0/3 14/21 3/0 13/7 5/4 17/19 1/3 4/1 4/3 |
| Combined/monotherapy during IT | 22/15 |
Conclusions
Our data suggest a better outcome on ensuing systemic therapies after IT. Further prospective investigations are needed to select the subset of patients who are more prone to a re-sensitization to CCT and to understand the mechanisms underlying.
Clinical trial identification
Legal entity responsible for the study
Clínica Universidad de Navarra.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
I. Melero: Advisory: BMS, Roche, AstraZeneca, Genmab, Alligator, Tusk, Bioncotech, Merck/Serono. All other authors have declared no conflicts of interest.
Resources from the same session
2300 - AXL has a prognostic role in metastatic colorectal cancer (mCRC) and is a predictive biomarker of lack of efficacy of chemotherapy (CT) + cetuximab in RAS wild type (WT) patients (pts)
Presenter: Claudia Cardone
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2834 - Multimodal detection of homologous recombination repair gene mutations (HRRm) in a Phase II trial of olaparib plus abiraterone in metastatic castrate resistant prostate cancer (mCRPC)
Presenter: Thomas Carr
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3596 - Identification of a highly suppressive Treg subset associated to immunotherapy response
Presenter: Emilio Giunta
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3705 - A Novel Framework for Evaluating Biomarker Response Relationships in Immuno-oncology (IO)
Presenter: Jeffrey Evelhoch
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5332 - Comparison of OncoBEAM and NGS methods to detect plasma EGFR T790M mutations at progression of NSCLC
Presenter: Jessica Garcia
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5700 - Differential expression of PD-L1 and immune biomarkers by age: Decreased expression in pediatric/AYA patients with advanced cancer
Presenter: Omid Hamid
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
966 - Potential resistance mechanisms revealed primary resistance to crizotinib in ROS1+ non-small-cell lung cancer using next generation sequencing: A multicenter study
Presenter: Quxia Zhang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2171 - Prevalence of CLDN18.2, HER2, and PD-L1 in Gastric Cancer Samples
Presenter: Diarmuid Moran
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2318 - Epigenetic markers in circulating cell-free DNA for detection of early stage colorectal cancer
Presenter: Yanqun Liu
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3625 - Detection and clearance of RET variants in plasma cell free DNA (cfDNA) from patients (pts) treated with LOXO-292
Presenter: Benjamin Besse
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract